History
History
2017
- 3 podium presentations held at World Vaccine Congress to highlight the potential of CALIXAR expertise in vaccine antigen preparation.
- 3 peer-reviewed articles accepted on membrane protein biochemistry and structural biology in collaboration with ASTRAZENECA, INMED, IGBMC and IBCP.
- Launching of CALIXAR catalogue of products and first contracts concluded with SAPPHIRE NORTH AMERICA and G-BIOSCIENCES for the distribution of membrane proteins and reagents.
- New CALIXAR™ C2B Additive Kit for crystallization launched and distributed by MOLECULAR DIMENSIONS.
- New patent published on antigen identification for Leptospirosis virulence (issued from the COVALEPT consortium with Merial, Genostar, Vetagro-Sup and Institut Pasteur).
- New patent published on new calixarene glycoside detergent and its use for extraction and stabilization of native functional membrane proteins.
- CALIXAR as invited speaker at Brussels University (VIB) membrane protein workshop.
2016
- Extension of strategic compounds portfolio for complex pharmaceutical targets isolation (new patent)
- French Inter-Ministry Fund award granted to 3-year program (Chikvax) for developing new vaccine against Chikungunya
- New review on “Overcoming bottlenecks in the membrane protein structural biology pipeline” (with Aston University)
- Official launch of the common laboratory CHEM2STAB with the University of Avignon
- New article published on novel Solubilization and Separation method (Analytical Biochemistry)
- New article published on native and functional ion channel isolation (Protein expression and purification)
2015
- New US Business Office opened in Cambridge, Massachusetts
- Patent on native isolation platform for complex therapeutic targets and antigens extended in Japan
- Bio’Innov Competitiveness’ Award upon the Entrepreneurship Spring Event
- €1 Million ($1,13 Million) second round funding with historical investors to license-out isolation technologies for complex therapeutic targets and viral antigens
2014
- Participation in the COST ion channel network project on the immune response
- New patent on innovative manufacturing process for high performance influenza vaccines
- Collaboration with Aston University on Multidrug Resistance Targets
- New patent on strategic compounds for complex pharmaceutical target isolation
2013
- Strategic marketing agreement with ABL Inc
- Innovation Prize from Rhône County
- New Calixarene additive kit for crystallization
2012
- €0,87 Million ($1.2 Million) first round funding with regional angels funds (Health Angels Rhone-Alpes, Veymont Finance, Grenoble Angels, Savoie Angels) and one VCs (Siparex)
- Involvement in COVALEPT project with SANOFI group, as leader for discovering and isolating new targets for leptospirosis vaccine development
2011
- CALIXAR founded by Emmanuel DEJEAN, Pierre FALSON (Research Director at the French National Research Center) and INP Entreprise as first investor